Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Prescient Therapeutics Limited ( (AU:PTX) ).
Prescient Therapeutics Limited announced the issuance of 12,942,721 unquoted equity securities in the form of options expiring on November 17, 2029, with an exercise price of $0.10. This move is part of an employee incentive scheme and is not intended for quotation on the ASX, reflecting the company’s strategy to incentivize and retain talent, potentially impacting its operational capabilities and market position.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative cancer therapies. The company’s primary products include targeted and personalized medicine solutions aimed at improving cancer treatment outcomes.
Average Trading Volume: 816,713
Technical Sentiment Signal: Buy
Current Market Cap: A$49.42M
Find detailed analytics on PTX stock on TipRanks’ Stock Analysis page.